Current opinion in ophthalmology Journal Impact Factor & Information

Publisher: Lippincott, Williams & Wilkins

Journal description

Topics Covered: Cataract Surgery and Lens Implantation; Glaucoma; Retina and Vitreous Disorders; Corneal and External Disorders and Refractive Surgery; Strabismus; Oculoplastic and Orbital Surgery; Neuro-ophthalmology; Ocular Manifestations of Systemic Disease.

Current impact factor: 2.64

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 2.638
2012 Impact Factor 2.557
2011 Impact Factor 2.647
2010 Impact Factor 2.429
2009 Impact Factor 2.49
2008 Impact Factor 2.958

Impact factor over time

Impact factor
Year

Additional details

5-year impact 0.00
Cited half-life 5.30
Immediacy index 0.35
Eigenfactor 0.01
Article influence 0.00
Website Current Opinion in Ophthalmology website
Other titles Current opinion in ophthalmology (Online), Current opinion in ophthalmology
ISSN 1531-7021
OCLC 36903873
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Lippincott, Williams & Wilkins

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Some journals have separate policies, please check with each journal directly
    • Pre-print must be removed upon acceptance for publication
    • Post-print may be deposited in personal website or institutional repository
    • Publisher's version/PDF cannot be used
    • Must include statement that it is not the final published version
    • Published source must be acknowledged with full citation
    • Set statement to accompany deposit
    • Must link to publisher version
    • NIH authors will have their accepted manuscripts transmitted to PubMed Central on their behalf after a 12 months embargo (see policy for details)
    • Wellcome Trust and HHMI authors will have their accepted manuscripts transmitted to PubMed Central on their behalf after a 6 months embargo (see policy for details)
    • Publisher last reviewed on 19/03/2015
  • Classification
    ‚Äč yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this review is to provide an update of phase 1 and 2 clinical trials in neovascular age-related macular degeneration that are either currently underway or recently completed by the end of 2014. Three gene therapy options are currently in early clinical trials, administered via intravitreal (AAV2-sFLT01) or subretinal (AVA-101 and RetinoStat) injection to express angiogenesis inhibitors. Several eye drops are being developed for topical administration for various angiogenic inhibitors, including regorafenib, squalamine lactate, and PAN-90806. Early development of systemic administration options may be intravenous (iSONEP) or oral (X-82). Initial study of local radiation therapy may be via proton beam irradiation or stereotactic radiotherapy. Several intravitreal injections are being studied including human immuno-conjugate molecule (hl-con1), abicipar pegol, PF582, DE-120, ESBA 1008, and REGN2176-3. Numerous treatment options of neovascular age-related macular degeneration are in phase 1/2 clinical trials including gene therapy, eye drops, systemic dosing, localized irradiation, and various intravitreal injections. Future phase 3 trial results will be observed closely to determine which of these therapies will be the next novel treatment of neovascular age-related macular degeneration.
    Current opinion in ophthalmology 03/2015; 26(3). DOI:10.1097/ICU.0000000000000147
  • [Show abstract] [Hide abstract]
    ABSTRACT: To describe the diagnosis and management of intraocular inflammation following antivascular endothelial growth factor (VEGF) injections. Inflammation following intravitreal anti-VEGF injections can cause a dramatic reduction in acuity. Differentiating factors from truly infectious endophthalmitis include a lack of pain, redness, or hypopyon, although none of these factors is diagnostic. A high suspicion of infectious endophthalmitis should trigger a prompt vitreous tap and injection of intravitreal antibiotics. Conversely, if noninfectious endophthalmitis is suspected, close observation with frequent topical steroids is warranted. Most eyes with noninfectious endophthalmitis following anti-VEGF injection recover within 1 month to baseline acuity with topical corticosteroid treatment. Mechanisms hypothesized to explain postinjection inflammation include patient-specific, delivery-specific, and medication-specific factors.
    Current opinion in ophthalmology 03/2015; DOI:10.1097/ICU.0000000000000154
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pneumatic retinopexy is an effective, cost-efficient procedure for retinal detachment repair. We review the history, indications, procedure, outcomes, economics, and trends regarding this in-office procedure. Pneumatic retinopexy is classically performed in patients with small, superior retinal breaks, but these indications are expanding, with good results. Retinal reattachment rates with pneumatic retinopexy vary from 60% to 91% depending upon patient selection. Pneumatic retinopexy is less costly to perform than scleral buckling and pars plana vitrectomy and avoids many of the complications associated with these procedures. Despite these good results, recent data suggest that the use of pneumatic retinopexy is on the decline. Recent review of the literature and our own personal experience using pneumatic retinopexy in selected cases of retinal detachment indicate that it is an effective and inexpensive procedure that avoids many of the complications that are associated with other retinal reattachment procedures.
    Current opinion in ophthalmology 03/2015; DOI:10.1097/ICU.0000000000000148
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review current concepts and future directions of corneal cross-linking (CXL) as a treatment for keratoconus, ectasia after refractive surgery and infectious keratitis. Several important laboratory and clinical studies have established the safety and success of corneal cross-linking for the treatment of keratoconus and other corneal ectasias. Recently, additional studies have analyzed new directions and controversies in corneal cross-linking, exploring new indications, comparing new techniques and analyzing results of new protocols. The results of bench and clinical research are providing the foundation to allow for protocol modifications of the standard cross-linking protocols and expansion of cross-linking concepts for techniques such as accelerated cross-linking, epithelium-sparing protocols and measurement of progression and success.
    Current opinion in ophthalmology 03/2015; 26(3). DOI:10.1097/ICU.0000000000000146
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review current status and future of ambulatory 24-h intraocular pressure monitoring. Despite important advances in the diagnosis and management of glaucoma during the last decade, the fundamental understanding of intraocular pressure, its only modifiable risk factor, remains elusive. The current practice of single intraocular pressure measurements during a clinic visit does not adequately reflect the variability of intraocular pressure throughout the 24-h day. There has been considerable progress recently with the prototype and commercial introduction of continuous 24-h intraocular pressure monitoring devices. Implantable intraocular pressure sensors have the advantage to directly measure intraocular pressure over many months and years, whereas temporary (contact lens based) approaches provide a noninvasive alternative for repeated 24-h periods. This review provides an overview of implantable devices as well as a critical assessment of a 24-h contact lens sensor. Recent advances in microelectromechanical systems and nanoelectromechanical systems have enabled the development of 24-h intraocular pressure monitoring devices. Once these technologies have shown their safety and efficacy, larger questions as to the data interpretation and handling will arise. It is likely that the use of 24-h intraocular pressure monitoring will herald fundamental changes in our understanding and management of glaucoma.
    Current opinion in ophthalmology 03/2015; 26(3). DOI:10.1097/ICU.0000000000000144
  • [Show abstract] [Hide abstract]
    ABSTRACT: To describe recent evidence regarding the clinical management of vitreomacular traction (VMT). Recent studies have reported favorable outcomes in patients with VMT managed with observation, pharmacologic vitreolysis with ocriplasmin, and intravitreal perfluoropropane gas. Subgroup analysis has identified features associated with spontaneous release of VMT as well as features associated with successful pharmacologic release of VMT with ocriplasmin. Observation may be an appropriate initial recommendation for patients with mild VMT. When treatment is necessary, pharmacologic vitreolysis with ocriplasmin is an effective nonsurgical therapeutic option. Careful patient selection improves success rates with ocriplasmin. Further study is necessary to establish the efficacy of intravitreal perfluoropropane gas for VMT as well as the efficacy of ocriplasmin in patients with VMT and concurrent retinal disease. As these treatments are more widely used, prospective data will continue to clarify their risk/benefit profile.
    Current opinion in ophthalmology 03/2015; 26(3). DOI:10.1097/ICU.0000000000000149
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review the pros and cons of small-gauge vitrectomy for symptomatic floaters. Current treatment options for floaters include Nd:YAG vitreolysis and pars plana vitrectomy. There are risks and benefits associated with vitrectomy for floaters. However, small-gauge vitrectomy is a minimally invasive way of removing the floaters. The current literature demonstrates vitrectomy has some risk, but is highly effective at improving vision, symptoms, contrast sensitivity, and quality of life. Small-gauge vitrectomy for floaters is a well tolerated and effective procedure to remove the symptomatic floaters. Symptomatic patients are willing to take some risk to have their troublesome vitreous floaters removed, often resulting in an improvement in their vision and quality of life.
    Current opinion in ophthalmology 03/2015; 26(3). DOI:10.1097/ICU.0000000000000150
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article discusses recent advances in the fundus-guided perimetry (microperimetry) and its utilization in evaluation and monitoring of patients with geographic atrophy. Although best-corrected visual acuity has been gold standard in clinical practice for decades, it does not provide an entire assessment of visual function that determines daily activity and quality of life of a patient. Furthermore, psychophysical tests, including low-luminance visual acuity, reading speed, and contrast sensitivity, cannot be used to quantify retinal sensitivity or detect pattern of retinal dysfunction. Microperimetry provides a true evaluation of visual function by offering fundus-controlled testing through eye-tracking technology that allows for structural and functional correlation and test-retest reliability for the same test point. Furthermore, it enables precise assessment of location and stability of fixation. Recent research has shown microperimetry to be more representative of the macular function in macular diseases. Microperimetry is currently the clinical investigation of choice to assess residual visual functions and functional vision in macular degenerative diseases, especially geographic atrophy. There is an increasing popularity to employ microperimetry in clinical trials investigating new treatments for geographic atrophy, as well as other macular degenerative diseases, as a reliable functional outcome measure.
    Current opinion in ophthalmology 03/2015; DOI:10.1097/ICU.0000000000000153
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ophthalmologists are dependent on computed tomography (CT) and MRI to aid in the diagnosis and management of patients with orbital and visual conditions. Pitfalls in the imaging process can lead to inefficient care or patient harm. This review summarizes these problems and provides methods to reduce imaging errors.
    Current opinion in ophthalmology 05/2014; DOI:10.1097/ICU.0000000000000064
  • [Show abstract] [Hide abstract]
    ABSTRACT: Asians make up the world's largest ethnic group, and the eyelid is one of the most prominent features of the face, regardless of race. Recent advances in Asian eyelid research have improved the understanding of its unique anatomy and, more importantly, highlighted differences surgeons should be aware of when performing Asian eyelid surgery.
    Current opinion in ophthalmology 05/2014; DOI:10.1097/ICU.0000000000000075
  • Current opinion in ophthalmology 05/2014; DOI:10.1097/ICU.0000000000000078
  • [Show abstract] [Hide abstract]
    ABSTRACT: Eye-bank preparation of endothelial tissue for keratoplasty continues to evolve. Although eye-bank personnel have become comfortable and competent at Descemet's stripping automated endothelial keratoplasty (DSAEK), tissue preparation and tissue transport, optimization of preparation methods continues. Surgeons and eye-bank personnel should be up to date on the research in the field. As surgeons transit to Descemet's membrane endothelial keratoplasty (DMEK), eye banks have risen to the challenge of preparing tissue. Eye banks are refining their DMEK preparation and transport techniques.
    Current opinion in ophthalmology 05/2014; DOI:10.1097/ICU.0000000000000060
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review the various steps and methods in managing residual refractive error after laser in situ keratomileusis and photorefractive keratectomy (PRK).
    Current opinion in ophthalmology 05/2014; DOI:10.1097/ICU.0000000000000059
  • [Show abstract] [Hide abstract]
    ABSTRACT: Astigmatism is a common refractive error that affects a significant portion of the population. This is a review of the most salient topics on assessing astigmatism as well as a discussion of the latest developments in surgical options and newest technologies to improve outcomes.
    Current opinion in ophthalmology 05/2014; DOI:10.1097/ICU.0000000000000068
  • [Show abstract] [Hide abstract]
    ABSTRACT: To update the knowledge on differences between mechanical microkeratome and femtosecond flaps for laser in-situ keratomileusis (LASIK) in terms of accuracy and complications.
    Current opinion in ophthalmology 05/2014; DOI:10.1097/ICU.0000000000000070
  • [Show abstract] [Hide abstract]
    ABSTRACT: This article reviews the current methods of improving outcomes when cataract surgery and endothelial keratoplasty are performed together.
    Current opinion in ophthalmology 05/2014; DOI:10.1097/ICU.0000000000000058
  • [Show abstract] [Hide abstract]
    ABSTRACT: Laser refractive surgery (LRS) is one of the most common elective procedures performed in the USA today. Patients should be rigorously screened for certain ocular and systemic conditions, which may represent contraindications to LRS. Before treating, the refractive surgeon should be aware of the Food and Drug Administration (FDA) labeling for the procedure as well as what other evidence, such as clinical studies, case series, cases reports, and anecdotal evidence, exists. The purpose of this article is to review contraindications to having LRS.
    Current opinion in ophthalmology 05/2014; DOI:10.1097/ICU.0000000000000055
  • [Show abstract] [Hide abstract]
    ABSTRACT: Corneal transplantation remains the gold-standard treatment for bullous keratopathy patients as it provides symptomatic relief and visual rehabilitation. As corneas are not always available for transplant, alternative treatments have to be considered for alleviation of discomfort and pain. Various treatment options available in such cases include conjunctival flaps, anterior stromal puncture, amniotic membrane transplantation, phototherapeutic keratectomy, bandage contact lenses, and hypertonic saline eye drops. A combination of the above treatments can be employed depending upon the severity of bullous keratopathy and co-existing corneal edema. New potential treatments include collagen cross-linking (CXL), cultured endothelial cell injection, and topical treatment with Rho-associated kinase (ROCK) inhibitor. There is a lack of clinical trials comparing the safety and efficacy of the currently available treatment options for the management of bullous keratopathy. The effect of these treatments on subsequent corneal transplant has not been observed. CXL seems to offer short-term benefit for relief of pain. Newer potential treatment modalities such as ROCK inhibitors are claimed to be useful for the reversal of early edema associated with corneal endothelial dysfunction; however, long-term clinical trials are awaited.
    Current opinion in ophthalmology 05/2014; DOI:10.1097/ICU.0000000000000062
  • [Show abstract] [Hide abstract]
    ABSTRACT: Descemet stripping endothelial keratoplasty has superseded penetrating keratoplasty (PKP) in adults as the procedure of choice for treating endothelial dysfunction, but endothelial keratoplasty despite the multitude of advantages has undergone a much slower adoption in pediatric patients. This review focuses on the recent advances made in the field of pediatric endothelial keratoplasty and the associated surgical challenges. Pediatric endothelial keratoplasty does not require as many sutures as PKP, and the wound size is smaller and more stable. Endothelial keratoplasty grafts clear faster, possibly allowing for a more effective management of amblyopia. Visual outcomes appear to be comparable with PKP but with a lower complication rate. As corneal surgeons grow more and more familiar with the nuances of pediatric endothelial keratoplasty, our understanding of this procedure will become more complete. The limited data available suggest that endothelial keratoplasty is a suitable surgical alternative to PKP in children.
    Current opinion in ophthalmology 05/2014; DOI:10.1097/ICU.0000000000000063